Head-To-Head Analysis: Moleculin Biotech (NASDAQ:MBRX) & NextCure (NASDAQ:NXTC)

NextCure (NASDAQ:NXTC) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for NextCure and Moleculin Biotech, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NextCure	1	0	3	0	2.50
Moleculin Biotech	1	0	2	0	2.33

NextCure presently has a consensus target price of $23.00, indicating a potential upside of 114.35%. Moleculin Biotech has a consensus target price of $22.00, indicating a potential upside of 873.02%. Given Moleculin Biotech’s higher possible upside, analysts clearly believe Moleculin Biotech is more favorable than NextCure.

Earnings & Valuation

This table compares NextCure and Moleculin Biotech”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NextCure	N/A	N/A	-$55.84 million	($20.00)	-0.54
Moleculin Biotech	N/A	N/A	-$33.56 million	($32.75)	-0.07

NextCure is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

42.7% of NextCure shares are held by institutional investors. Comparatively, 15.5% of Moleculin Biotech shares are held by institutional investors. 13.3% of NextCure shares are held by company insiders. Comparatively, 1.1% of Moleculin Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares NextCure and Moleculin Biotech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NextCure	N/A	-152.90%	-109.17%
Moleculin Biotech	N/A	-1,092.49%	-60.88%

Volatility & Risk

NextCure has a beta of 1.5, meaning that its stock price is 50% more volatile than the S&P 500. Comparatively, Moleculin Biotech has a beta of 1.73, meaning that its stock price is 73% more volatile than the S&P 500.

Summary

NextCure beats Moleculin Biotech on 6 of the 11 factors compared between the two stocks.

About NextCure

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.

About Moleculin Biotech

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.